OBJECTIVE: Individuals with early-onset dysexecutive Alzheimer's disease (dAD) have high rates of failed performance validity testing (PVT), which can lead to symptom misinterpretation and misdiagnosis. METHOD: The aim of this retrospective study is to evaluate rates of failure on a common PVT, the test of memory malingering (TOMM), in a sample of clinical patients with biomarker-confirmed early-onset dAD who completed neuropsychological testing. RESULTS: We identified seventeen patients with an average age of symptom onset at 52.25 years old. Nearly fifty percent of patients performed below recommended cut-offs on Trials 1 and 2 of the TOMM. Four of six patients who completed outside neuropsychological testing were misdiagnosed with alternative etiologies to explain their symptomatology, with two of these patients' performances deemed unreliable based on the TOMM. CONCLUSIONS: Low scores on the TOMM should be interpreted in light of contextual and optimally biological information and do not necessarily rule out a neurodegenerative etiology.
OBJECTIVE: Individuals with early-onset dysexecutive Alzheimer's disease (dAD) have high rates of failed performance validity testing (PVT), which can lead to symptom misinterpretation and misdiagnosis. METHOD: The aim of this retrospective study is to evaluate rates of failure on a common PVT, the test of memory malingering (TOMM), in a sample of clinical patients with biomarker-confirmed early-onset dAD who completed neuropsychological testing. RESULTS: We identified seventeen patients with an average age of symptom onset at 52.25 years old. Nearly fifty percent of patients performed below recommended cut-offs on Trials 1 and 2 of the TOMM. Four of six patients who completed outside neuropsychological testing were misdiagnosed with alternative etiologies to explain their symptomatology, with two of these patients' performances deemed unreliable based on the TOMM. CONCLUSIONS: Low scores on the TOMM should be interpreted in light of contextual and optimally biological information and do not necessarily rule out a neurodegenerative etiology.
Authors: Jerry J Sweet; Robert L Heilbronner; Joel E Morgan; Glenn J Larrabee; Martin L Rohling; Kyle B Boone; Michael W Kirkwood; Ryan W Schroeder; Julie A Suhr Journal: Clin Neuropsychol Date: 2021-04-06 Impact factor: 3.535
Authors: Clifford R Jack; David S Knopman; Stephen D Weigand; Heather J Wiste; Prashanthi Vemuri; Val Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Robert J Ivnik; Rosebud O Roberts; Walter A Rocca; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2012-04-09 Impact factor: 10.422
Authors: Stevie Hendriks; Kirsten Peetoom; Christian Bakker; Wiesje M van der Flier; Janne M Papma; Raymond Koopmans; Frans R J Verhey; Marjolein de Vugt; Sebastian Köhler; Adrienne Withall; Juliette L Parlevliet; Özgül Uysal-Bozkir; Roger C Gibson; Susanne M Neita; Thomas Rune Nielsen; Lise C Salem; Jenny Nyberg; Marcos Antonio Lopes; Jacqueline C Dominguez; Ma Fe De Guzman; Alexander Egeberg; Kylie Radford; Tony Broe; Mythily Subramaniam; Edimansyah Abdin; Amalia C Bruni; Raffaele Di Lorenzo; Kate Smith; Leon Flicker; Merel O Mol; Maria Basta; Doris Yu; Golden Masika; Maria S Petersen; Luis Ruano Journal: JAMA Neurol Date: 2021-09-01 Impact factor: 29.907